Get the Stockscreener App
6.36
5.22%
-0.35
After Hours:
6.40
0.04
+0.63%
Personalis Inc stock is traded at $6.36, with a volume of 1.75M.
It is down -5.22% in the last 24 hours and down -4.07% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$6.71
Open:
$6.52
24h Volume:
1.75M
Relative Volume:
0.97
Market Cap:
$666.03M
Revenue:
$69.65M
Net Income/Loss:
$-81.27M
P/E Ratio:
-6.9982
EPS:
-0.9088
Net Cash Flow:
$-79.45M
1W Performance:
+6.35%
1M Performance:
-4.07%
6M Performance:
-15.31%
1Y Performance:
+30.06%
1-Day Range:
$6.32
$6.59
1-Week Range:
$5.70
$7.3925
52-Week Range:
$3.84
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.36 | 702.68M | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis rises as Medicare coverage for NeXT Personal test expands - MSN
Personalis to Participate in Upcoming Investor Events - BioSpace
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (NASDAQ: PSNL) director granted 6,250 RSUs and 37,500 options - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and 37,500-share stock option - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and options as board pay - Stock Titan
Personalis (PSNL) director Olivia Bloom granted RSUs and 37,500 options - Stock Titan
Personalis (PSNL) director receives 6,250 RSUs and 37,500 options - Stock Titan
Personalis Shares Rise on Medicare Coverage for Immunotherapy Monitoring - Moomoo
Personalis Shareholders Back Directors, Auditor and Executive Pay - TipRanks
Personalis shareholders elect directors and approve proposals at annual meeting - Investing.com India
Lake Street Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $11 - Moomoo
Personalis (NASDAQ: PSNL) investors back directors, executive pay and BDO as auditor - Stock Titan
Expanded Medicare coverage for Personalis (NASDAQ: PSNL) NeXT Personal test - Stock Titan
Personalis Inc (NASDAQ: PSNL) Share Price, PSNL Stock News, PSNL Share Price & Updates - Kalkine
Personalis (PSNL) Q1 2026 Earnings Transcript - AOL.com
Personalis (PSNL) Expands Coverage for NeXT Personal MRD Test - GuruFocus
Why is Personalis stock surging today? By Investing.com - Investing.com Canada
Personalis receives Medicare coverage for Next Personal for immunotherapy monitoring across late-stage solid tumors - marketscreener.com
Personalis gains expanded Medicare coverage for cancer test - Investing.com
Personalis gains expanded Medicare coverage for cancer test By Investing.com - Investing.com UK
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
PSNL Maintained by Morgan Stanley -- Price Target Lowered to $9. - GuruFocus
Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026 - Stock Titan
PSNL: Directors and auditors elected, executive pay approved, with strong growth and AI focus - TradingView
Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating - Moomoo
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Cuts Target Price to $5.78 - Moomoo
PSNL Maintained by BTIG -- Price Target Lowered to $11.00 - GuruFocus
BTIG Research Issues Pessimistic Forecast for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
BTIG cuts Personalis stock price target on lab sector valuation - Investing.com
BTIG cuts Personalis stock price target on lab sector valuation By Investing.com - Investing.com Nigeria
Personalis, Inc. (NASDAQ:PSNL) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim Remains a Buy on Personalis (PSNL) - The Globe and Mail
Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Personalis Q1 Earnings Call Highlights - Barchart.com
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Q1 2026 Personalis Inc Earnings Call Transcript - GuruFocus
Guggenheim Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Needham reiterates Personalis stock rating citing MRD growth By Investing.com - Investing.com Australia
Personalis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham reiterates Personalis stock rating citing MRD growth - Investing.com UK
Personalis, Inc. (PSNL) Stock Analysis: Navigating a Promising 88% Upside in Healthcare Genomics - DirectorsTalk Interviews
Personalis: Q1 Earnings Snapshot - theheraldreview.com
Personalis Reports First Quarter Results and Recent Highlights - BioSpace
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss - Investing.com
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss By Investing.com - Investing.com South Africa
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):